Survival analysis of patients with locally advanced non-small cell lung cancer treated at the Nu-Med Radiotherapy Center in Elbląg

Marcin Kurowicki¹, Karolina Osowiecka², Sergiusz Nawrocki³, Łukasz Cieśliński¹, Barbara Szostakiewicz¹, Andrzej Badzio⁴

¹Nu-Med Radiotherapy Center, Elbląg, Poland
²Department of Psychology and Sociology of Health and Public Health, School of Public Health, University of Warmia and Mazury in Olsztyn, Poland
³Department of Public Health, Medical University of Warsaw, Poland
⁴Department of Oncology, Faculty of Medical Sciences, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland

Introduction. The study aimed to report the efficiency of radical radiotherapy and chemoradiotherapy in patients with non-small cell lung cancer (NSCLC) treated in the Nu-Med Radiotherapy Center in Elbląg.

Material and methods. Ninety-two patients diagnosed with NSCLC treated between 2013 and 2016 were included in the analysis. Overall survival (OS) was estimated by the Kaplan-Meier method.

Results. The 2-year OS for all patients was 36% (median 1.5 years). Two prognostic factors had a significant impact: treatment method and performance status (PS). Patients who underwent concurrent radiochemotherapy and were treated sequentially had a better 2-year OS in comparison with those treated with radiotherapy alone (respectively 46% and 37% vs. 25%, p ≤ 0.05). Patients with PS 0–1 had better OS (median 1.6 years) compared with PS 2 (median 0.7 years, p = 0.04). Other prognostic factors analysed had no impact on OS in our study.

Conclusions. The treatment results of our patients are comparable to those in published trials and meta-analyses.

Key words: non-small cell lung cancer, chemoradiotherapy, radiotherapy, overall survival

How to cite: Kurowicki M, Osowiecka K, Nawrocki S, Cieśliński Ł, Szostakiewicz B, Badzio A. Survival analysis of patients with locally advanced non-small cell lung cancer treated at the Nu-Med Radiotherapy Center in Elbląg. NOWOTWORY J Oncol 2020; 70: 135–143.
NSCLC surgery remains the primary treatment; for locally advanced non-small cell lung cancer chemoradiotherapy is the treatment of choice. However, the effectiveness of the latter leaves much to be desired. We have particularly high hopes for the addition of immunotherapy to chemoradiotherapy, which has significantly improved survival in inoperable patients [8].

However, there are some limitations to the data supporting treatment strategies in specific patient subsets and studies have included heterogeneous patient populations. The definition of clinical stage III has changed over time, and early reviews have often been inadequately powered to detect small differences in survival outcome, have not been randomised or have had limited time of follow-up. Development in therapy: the use of more active chemotherapy agents and refinements in radiation and surgical techniques also limit the interpretation of earlier clinical trials [9]. The aim of this study was to analyse and report the outcome of the treatment of non-small cell lung cancer patients with radical radiotherapy and chemoradiotherapy in our department.

Material and methods
A list of patients was generated from the institutional database, Mosaq and Clinicnet systems. The medical records of all patients were available for this study. The research was conducted on a group of 109 patients with primary, unresectable, non-metastatic cancers, with a histopathological diagnosis of non-small cell lung cancer, who underwent curative radio- and radiochemotherapy between 2013 and 2016 in the Nu-Med Radiotherapy Center in Elbląg. Seventeen patients were excluded from the analysis. The reason for exclusion was resection in 11 patients (10%), including nine patients treated with postoperative radiation and two patients treated with preoperative radiochemotherapy. Six patients (6%) who underwent therapy because of recurrence were also excluded from the analysis. All patients were staged with computed tomography of the chest and abdominal ultrasound, 57 (62%) had PET examinations, 87 (95%) had a spirometric evaluation.

The stage was determined by the UICC TNM classification of Malignant Tumours – 7th edition. A total dose of 66 Gy with fraction dose 2 Gy was administrated in 55 patients, 66 Gy (fraction dose 2.2 Gy) in 8 patients, 60 Gy (fraction dose 2 Gy) in 27 cases and 50 Gy in 2 patients. Dose 60 Gy was prescribed for concomitant treatment, 66 Gy for the sequential scheme or for radiotherapy alone. The dose of 50 Gy was prescribed for tumours infiltrating vertebral bodies close to the spine. The CTV included lung tumour and pathological lymph nodes with 8 mm margins. In post-chemotherapy cases, the CTV consisted of residual lung tumour and lymph nodes with an 8 mm margin and initially involved mediastinal node groups. In both scenarios, the PTV was created by adding 7 mm margins radially and 10 mm in the craniocaudal direction.

Treatment plans were prepared using Prowess or Eclipse software. Radiotherapy was delivered with Artiste (Siemens) Linacs, using photons X 6 MV, with IMRT in 79 patients (86%) and 3D technique in 13 (14%). The method was chosen by attending a radiation oncologist, after DVH comparison.

Patients treated with chemoradiotherapy received different chemotherapy regimens: carboplatin-vinorelbine (KN) (6 patients), cisplatin-vinorelbine (PN) (47 patients), carboplatin-etoposide (KE) (1 patient), cisplatin-etoposide (PE) (6 patients), cisplatin (1 patient), cisplatin-pemetrexed (1 patient), KN+PN (1 patient), KN+PXL/CDDP (1 patient). The induction chemotherapy regimen was chosen and administered by medical oncologists from other hospitals.

The efficacy of radiotherapy and chemoradiotherapy was estimated by survival analysis from the date of the beginning of the treatment to the last follow-up visit/death. Variables that can impact patient survival (sex, age, BMI, place of residence, the distance between the place of residence and Nu-Med Center, baseline WHO PS, clinical stage, lymph node status, tumour localisation, type of histopathology, type of treatment) were analysed.

The proportion between subgroups: radiotherapy alone vs. sequential radiochemotherapy vs. concurrent radiochemotherapy in different factors were compared using the chi² test. Overall survival (OS) was estimated by the Kaplan-Meier method and differences in survival were compared by the log-rank test. Uni- and multivariable analysis was estimated through the Cox regression model. Univariate variables with p < 0.25 were included in the multivariable analysis. A p-value <0.05 was considered to be significant. The analysis was performed using TIBCO Software Inc. (2017) and Statistica (a data analysis software system), version 13. http://statistica.io

Results
Ninety-two patients were included in the analysis. The majority of patients were men (72; 78%) and lived in cities ≤100 thousand (44; 48%) and villages (31; 34%). The median age was 64 years. Half of the patients (47; 51%) were of PS (performance status) grade 0 according to the WHO/ECOG scale during the first visit. Most patients were treated in clinical stage IIIA (53; 58%) and IIIB (31; 34%), with T3–4 (70%), with N2–3 (80%), with squamous cell carcinoma (68; 74%) and adenocarcinoma (19; 21%), tumour localisation on right side (59; 64%). Over half (57; 62%) had a PET examination before treatment. 28 patients (30%) underwent radiotherapy only, 38 patients (41.5%) had sequential radiochemotherapy and 26 patients (28.5%) had concurrent radiochemotherapy. Most patients (58; 63%) were referred from Szpital Specializatyeczny in Prabuty (the regional pulmonological center) for treatment to the Nu-Med Center and the 34 remaining patients (37%) where diagnosed in hospitals in Elbląg (tab. I).

More patients who received radiotherapy alone were >64 years compared with patients who underwent sequential or concurrent radiochemotherapy, respectively 89% vs. 32% vs. 23% (p < 0.001). There was a significant difference in perfor-
Table I. Characteristics of patients

| Patient's characteristic                  | All          | Radiotherapy alone | Sequential radiochemotherapy | Concurrent radiochemotherapy | Chi² test |
|------------------------------------------|--------------|--------------------|------------------------------|----------------------------|-----------|
|                                          | N    | %    | N    | %    | N    | %    | N    | %    | p  |          |
| Age (start of radiotherapy)              |      |      |      |      |      |      |      |      |    |          |
| ≤64                                      | 49   | 53   | 3    | 11  | 26   | 68   | 20   | 77  | <0.001 |          |
| >64                                      | 43   | 47   | 25   | 89  | 12   | 32   | 6    | 23  | 0.46   |          |
| Sex                                      |      |      |      |      |      |      |      |      |    |          |
| women                                    | 20   | 22   | 5    | 18  | 9    | 24   | 6    | 23  | 0.84   |          |
| men                                      | 72   | 78   | 23   | 82  | 29   | 76   | 20   | 77  |        |          |
| BMI                                      |      |      |      |      |      |      |      |      |    |          |
| ≤26                                      | 42   | 46   | 15   | 53.5| 18   | 47   | 9    | 34.5| 0.46   |          |
| >26                                      | 42   | 46   | 12   | 43  | 16   | 42   | 14   | 54  |        |          |
| no data                                  | 8    | 9    | 1    | 3.5 | 4    | 11   | 3    | 11.5|        |          |
| Place of residence                       |      |      |      |      |      |      |      |      |    |          |
| village                                  | 31   | 34   | 9    | 32  | 13   | 34   | 9    | 34.5| 0.08   |          |
| cities ≤100 thous                        | 44   | 48   | 14   | 50  | 22   | 58   | 8    | 31  |        |          |
| cities >100 thous                        | 17   | 18   | 5    | 18  | 3    | 8    | 9    | 34.5|        |          |
| Distance from place of residence to Nu-Med. Center |      |      |      |      |      |      |      |      |    |          |
| ≤67                                      | 47   | 51   | 13   | 46  | 17   | 45   | 17   | 65  | 0.22   |          |
| >67                                      | 45   | 49   | 15   | 54  | 21   | 55   | 9    | 35  |        |          |
| Performance status according WHO/ECOG during first visit |      |      |      |      |      |      |      |      |    |          |
| 0                                        | 47   | 51   | 10   | 36  | 17   | 45   | 20   | 77  | 0.02   |          |
| 1                                        | 37   | 40   | 14   | 50  | 17   | 45   | 6    | 23  |        |          |
| 2                                        | 8    | 9    | 4    | 14  | 4    | 10   | 0    | 0   |        |          |
| Clinical stage                           |      |      |      |      |      |      |      |      |    |          |
| IB                                       | 3    | 3    | 3    | 11  | 0    | 0    | 0    | 0   | 0.02   |          |
| IIA                                      | 2    | 2    | 2    | 7   | 0    | 0    | 0    | 0   |        |          |
| IIb                                      | 3    | 3    | 2    | 7   | 1    | 3    | 0    | 0   |        |          |
| IIIA                                     | 53   | 58   | 16   | 57  | 19   | 50   | 18   | 69  |        |          |
| IIIB                                     | 31   | 34   | 5    | 18  | 18   | 47   | 8    | 31  |        |          |
| Lymph nodes status                       |      |      |      |      |      |      |      |      |    |          |
| N+                                       | 79   | 86   | 20   | 71  | 35   | 92   | 24   | 92  | 0.03   |          |
| N–                                       | 13   | 14   | 8    | 29  | 3    | 8    | 2    | 8   |        |          |
| Tumor localization                       |      |      |      |      |      |      |      |      |    |          |
| right                                    | 59   | 64   | 17   | 61  | 26   | 68   | 16   | 61  | 0.97*  |          |
| left                                     | 29   | 32   | 9    | 32  | 12   | 32   | 8    | 31  |        |          |
| mediastinum                              | 3    | 3    | 2    | 7   | 0    | 0    | 1    | 4   |        |          |
| right and left                           | 1    | 1    | 0    | 0   | 0    | 0    | 1    | 4   |        |          |
| Type of histopathology                   |      |      |      |      |      |      |      |      |    |          |
| planoepitheliale                         | 68   | 74   | 19   | 68  | 30   | 79   | 19   | 73  | 0.74^  |          |
| adenocarcinoma                           | 19   | 21   | 7    | 25  | 7    | 18   | 5    | 19  |        |          |
| undetermined                             | 5    | 5    | 2    | 7   | 1    | 3    | 2    | 8   |        |          |
| PET                                      |      |      |      |      |      |      |      |      |    |          |
| yes                                      | 57   | 62   | 21   | 75  | 14   | 37   | 22   | 85  | <0.001 |          |
| no                                       | 35   | 38   | 7    | 25  | 24   | 63   | 4    | 15  |        |          |
Performance status (PS) according to the WHO/ECOG classification during the first visit between patients treated with concurrent radiochemotherapy (no one with PS 2) vs. sequential radiochemotherapy (10% of patients with PS 2) or radiotherapy alone (14% of patients with PS 2) (p = 0.02). Patients who underwent a different type of treatment significantly differed in terms of characteristics: clinical stage, lymph node status, PET examination and the time of treatment from radiochemotherapy to the end of radiotherapy (tab. I).

The 2-year overall survival for all patients was 36%. The median OS (mOS) was 1.5 years (95% confidence interval (CI): 0.7–2.8 years; fig. 1). 31 deaths (34%) were observed during the first year, including 13 patients treated with radiotherapy alone, 9 with sequential radiochemotherapy and 9 with concurrent radiochemotherapy. Patients who underwent radiotherapy alone had a statistically significant worse 2-year OS (25%; mOS 1.1 years [95% CI: 0.5–1.9 years]) in comparison with patients treated with concurrent (46%; mOS 1.1 years [95% CI: 0.5–not reached]; p = 0.05) and sequential radiochemotherapy (37%; mOS 1.7 years [95% CI: 1.0–2.6 years]; p = 0.03). There was no significant difference observed between concurrent and sequential radiochemotherapy (p = 0.54) (fig. 2, tab. II). Patients with PS 0–1 during the first consultation had a significantly better mOS – 1.6 years (95% CI: 0.7–3.5 years) than patients with PS 2 – mOS 0.7 years (95% CI: 0.4–1.1 years; p = 0.04) (fig. 3, tab. II). Total treatment time, age, sex, BMI, place of residence, the distance from the place of residence to the Nu-Med Center, lymph node metastasis, tumour localisation, type of histopathology, clinical stage, PET examination had no impact on OS (tab. II).

### Table II. Overall survival of patients

| Patient’s characteristic | All | Radiotherapy alone | Sequential radiochemotherapy | Concurrent radiochemotherapy | chi² test |
|--------------------------|-----|--------------------|-------------------------------|-----------------------------|----------|
| Time of treatment from radiochemotherapy to end of radiotherapy | N | % | N | % | N | % | N | % | p |
| ≤47.5 | 46 | 50 | 26 | 93 | 0 | 0 | 20 | 77 | <0.001 |
| >47.5 | 46 | 50 | 2 | 7 | 38 | 100 | 6 | 23 | |

*p-value – comparison of the percentages between subgroups: right and left tumor localization

*^p-value – comparison of the percentages between subgroups: planoepitheliale and adenocarcinoma type of histopathology
| Performance status according to WHO/ECOG scale during first visit | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|---------------------------------------------------------------|--------------|----------------------------|-----------------|
| 0–1                                                          | 39           | 1.6 (0.7–3.5)              | 0.04            |
| 2                                                            | –            | 0.7 (0.4–1.1)              |                 |

| Clinical stage | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|----------------|--------------|----------------------------|-----------------|
| IB             | 33           | 1.9 (0.4–4.1)              | 0.63            |
| IIA            | 50           | 0.2 (0.2–2.3)              |                 |
| IIB            | –            | 0.6 (0.5–1.7)              |                 |
| IIA–B          | 37           | 1.5 (0.7–3.1)              |                 |

| Lymph node status | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|-------------------|--------------|----------------------------|-----------------|
| N+                | 37           | 1.5 (0.7–2.6)              | 0.78            |
| N–                | 31           | 1.7 (0.5–3.1)              |                 |

| Tumor localization | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|--------------------|--------------|----------------------------|-----------------|
| right              | 38           | 1.6 (0.7–2.6)              | 0.51*           |
| left               | 38           | 1.6 (0.7–not reached)      |                 |

| Type of histopathology | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|------------------------|--------------|----------------------------|-----------------|
| planoepitheliaplae     | 32           | 1.5 (0.6–2.2)              | 0.29^           |
| adenocarcinoma         | 47           | 1.6 (1.0–4.2)              |                 |

| PET | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|-----|--------------|----------------------------|-----------------|
| yes | 40           | 1.5 (0.6–3.6)              | 0.52            |
| no  | 28           | 1.5 (0.7–2.1)              |                 |

| Time of treatment from radiochemotherapy to end of radiotherapy | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|----------------------------------------------------------------|--------------|----------------------------|-----------------|
| ≤47.5 days                                                      | 37           | 1.2 (0.5–2.6)              | 0.55            |
| >47.5 days                                                     | 35           | 1.6 (1.0–2.6)              |                 |

| Type of treatment | 2-year OS (%) | Median OS [years] (95% CI) | Log-Rank test p |
|-------------------|--------------|----------------------------|-----------------|
| alone radiotherapy| 25           | 1.1 (0.5–1.9)              | 0.07            |
| sequential radiochemotherapy | 37 | 1.7 (1.0–2.6) |                 |
| concurrent radiochemotherapy | 46 | 1.1 (0.5–not reached) | |

* patients with mediastinum tumor localization were excluded from the analysis
^ patients with undetermined type of histopathology were excluded from the analysis

Figure 1. Overall survival for all patients

Figure 2. Overall survival by type of treatment
In univariate analysis, only three factors met the inclusion criteria to a multivariate regression model (p < 0.25). In multivariate analysis, it was determined that performance status and type of treatment were independent factors influencing OS. The risk of death in patients with WHO/ECOG grade 2 increased by three times (PS 0–1 vs. 2, HR: 3.0; 95% CI: 1.4–6.6; p = 0.006). Increased risk of death was observed in patients treated with radiotherapy alone (HR: 2.4; 95% CI: 1.0–5.6; p = 0.04) compared with concurrent radiochemotherapy (tab. III).

**Discussion**

The optimal management of NSCLC patients depends on multiple factors, including the clinical stage of the disease, the potential to achieve a complete resection, the patient’s overall condition, comorbidities and preferences. The main option for CS I–IIIA (N0–1) NSCLC remains surgery, for clinical stages: IIIA (N2), IIIB, and unresectable I–IIIA (N0–1) the standard of care is radiochemotherapy [10].

The current analysis concerned patients qualified for treatment before and after the Polish National Program of Diagnosis and Treatment of Oncological Diseases was set. Before 2015, in our centre, the decision to use the appropriate treatment was made by a team of radiation oncologists, after disqualification from surgery by thoracic surgeons. In 2015, we started to present patients at a multidisciplinary board with a radiation oncologist, a medical oncologist, a radiologist and a thoracic surgeon, where an accurate treatment plan was chosen.

Curative radiotherapy alone was chosen for elders and patients with a poorer performance status, who had con-

| Variables                                      | Univariate analysis | Multivariate analysis |
|------------------------------------------------|---------------------|-----------------------|
| **Age (start of radiotherapy)**                |                     |                       |
| ≤64 years                                      | 1.0 reference       | 1.0 reference         |
| >64 years                                      | 1.4 (0.9–2.2)       | 0.17 0.79 (0.4–1.6)   |
| **Sex**                                        |                     |                       |
| women                                          | 1.0 reference       |                       |
| men                                            | 1.3 (0.7–2.3)       | 0.43                  |
| **BMI**                                        |                     |                       |
| ≤26                                            | 1.0 reference       |                       |
| >26                                            | 0.9 (0.6–1.5)       | 0.76                  |
| **Place of residence**                         |                     |                       |
| village                                        | 1.0 reference       |                       |
| cities ≤100 thous                              | 1.2 (0.7–2.0)       | 0.59                  |
| cities >100 thous                              | 1.1 (0.6–2.2)       | 0.97                  |
| **Distance from place of residence to Nu-Med Center** |     |                       |
| >67 km                                         | 1.0 reference       |                       |
| ≤67 km                                         | 1.3 (0.8–2.1)       | 0.30                  |
| **Performance status according to WHO/ECOG scale during first visit** | |                       |
| 0–1                                           | 1.0 reference       | 1.0 reference         |
| 2                                             | 2.9 (1.4–6.3)       | 0.006 3.0 (1.4–6.6)   |

Figure 3. Overall survival by performance status during the first visit
indications to chemotherapy or in whom the application of the combined treatment would significantly increase its toxicity. The 2-year overall survival of our patients treated with radiotherapy only was 25% and this was at the upper limit of the survival time reported in the literature: 5–28% [11–15].

Patients in good general condition without significant comorbidities were qualified for combined therapies. At multidisciplinary meetings, concurrent radiochemotherapy was the preferred option. Sequential treatment was selected when the baseline tumour volume excluded radical radiotherapy and chemotherapy would provide a chance to reduce tumour mass (more advanced clinical stage, positive lymph node status).

The addition of chemotherapy to radiation has been the subject of many trials and several meta-analyses. Firstly, its beneficial influence on survival was demonstrated in the case of sequential radiochemotherapy in comparison with radical radiation alone. Adding induction chemotherapy to radiotherapy increased overall survival to 26–31% at two years [14, 16–18]. Secondly, the introduction of concurrent radiochemotherapy: although this intensification of treatment is associated with higher toxicity, most trials showed better survival with a concurrent association in comparison with sequential therapy [17, 19–24]. Combining chemotherapy and radiotherapy simultaneously increases 2-year overall survival to 35.6–55.6% [8, 17, 18, 23].

Our study showed the significant advantage of radiochemotherapy in survival outcomes when compared with radiotherapy alone. The 2-year survival of NSCLC patients treated with sequential and concomitant radiochemotherapy was 37% and 46% respectively. The results were comparable to those published in clinical trials and meta-analyses. However, this report did not manage to show a significant difference in

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
| Clinical stage      |                       |
| IB                  | 1.0                   |
| IIA                 | 1.3 (0.2–7.9)         |
| IIIB                | 2.1 (0.4–10.4)        |
| IIIB–IIIA–IIIB      | 0.8 (0.3–2.7)         |
| Lymph nodes status |                       |
| N–                  | 1.0                   |
| N+                  | 1.1 (0.6–2.2)         |
| Tumor localization |                       |
| left                | 1.0                   |
| right               | 1.2 (0.7–2.0)         |
| Type of histopathology |                   |
| adenocarcinoma      | 1.0                   |
| planoepitheliale    | 1.4 (0.7–2.4)         |
| PET                 |                       |
| yes                 | 1.0                   |
| no                  | 1.2 (0.7–1.9)         |
| Time of treatment from radiochemotherapy to end of radiotherapy | |
| >47.5 days          | 1.0                   |
| ≤47.5 days          | 1.2 (0.7–1.8)         |
| Type of treatment   |                       |
| concurrent radiochemotherapy | 1.0 |
| alone radiotherapy  | 2.1 (1.1–4.1)         |
| sequential radiochemotherapy | 1.2 |
| alone radiotherapy  | 2.1 (1.1–4.1)         |
| sequential radiochemotherapy | 1.2 |

* patients with mediastinum tumor localization were excluded from the analysis
^ patients with undetermined type of histopathology were excluded from the analysis

radiation alone. Adding induction chemotherapy to radiotherapy increased overall survival to 26–31% at two years [14, 16–18]. Secondly, the introduction of concurrent radiochemotherapy: although this intensification of treatment is associated with higher toxicity, most trials showed better survival with a concurrent association in comparison with sequential therapy [17, 19–24]. Combining chemotherapy and radiotherapy simultaneously increases 2-year overall survival to 35.6–55.6% [8, 17, 18, 23].

Our study showed the significant advantage of radiochemotherapy in survival outcomes when compared with radiotherapy alone. The 2-year survival of NSCLC patients treated with sequential and concomitant radiochemotherapy was 37% and 46% respectively. The results were comparable to those published in clinical trials and meta-analyses. However, this report did not manage to show a significant difference in

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
| Clinical stage      |                       |
| IB                  | 1.0                   |
| IIA                 | 1.3 (0.2–7.9)         |
| IIIB                | 2.1 (0.4–10.4)        |
| IIIB–IIIA–IIIB      | 0.8 (0.3–2.7)         |
| Lymph nodes status |                       |
| N–                  | 1.0                   |
| N+                  | 1.1 (0.6–2.2)         |
| Tumor localization |                       |
| left                | 1.0                   |
| right               | 1.2 (0.7–2.0)         |
| Type of histopathology |                   |
| adenocarcinoma      | 1.0                   |
| planoepitheliale    | 1.4 (0.7–2.4)         |
| PET                 |                       |
| yes                 | 1.0                   |
| no                  | 1.2 (0.7–1.9)         |
| Time of treatment from radiochemotherapy to end of radiotherapy | |
| >47.5 days          | 1.0                   |
| ≤47.5 days          | 1.2 (0.7–1.8)         |
| Type of treatment   |                       |
| concurrent radiochemotherapy | 1.0 |
| alone radiotherapy  | 2.1 (1.1–4.1)         |
| sequential radiochemotherapy | 1.2 |

* patients with mediastinum tumor localization were excluded from the analysis
^ patients with undetermined type of histopathology were excluded from the analysis
efficiency between sequential and concomitant therapy. This could be limited by the small size of the subgroups compared. Unfortunately, our center, especially in the first years of operation, had no impact on the choice of combination therapy (simultaneous vs. sequential). The majority of patients who were suitable for concurrent treatment were referred to our department with no initial PET-CT scan and after the administration of induction chemotherapy – without the decision of a multidisciplinary board.

In the multivariate analysis, the type of treatment and performance status were independent factors influencing OS. We estimated the statistically significant increasing risk of death in patients treated with radiotherapy alone in comparison with concurrent chemoradiotherapy and in patients with WHO/ECOG grade 2 at the first consultation. Polish colleagues also confirmed that performance status had a significant association with overall survival [25]. In our analyses, four PS 2 patients were treated with sequential chemoradiotherapy, and their ECOG status was probably an effect of the extent of disease and chemotherapy toxicity.

In Poland, apart from clinical trials, institutional reports on the effectiveness of oncologic treatment of lung cancer are still lacking. A similar type of institutional report with a survival analysis of NSCLC patients was noted in the case of patients treated in the Warmia and Mazuria Oncology Center in Olsztyn, Poland. The authors showed treatment results for 130 patients treated with chemoradiotherapy in CS IIIA–IIIB and the 2-year overall survival was 37% [25]. The results are consistent with those reported by our analysis.

Nonetheless, we are aware of the limitations of this study. It is a retrospective analysis, with a small sample and a short observation time. Comparison of the groups also has limited value because of the small subgroups and potential selection bias.

Conclusions
The survival data of NSCLC patients treated in the Nu-Med Radiotherapy Center in Elblag is comparable to those published in other papers. Forty-six percent of patients treated with concurrent radiochemotherapy survived 2 years. The main risk factors which decreased OS were: the type of therapy and performance status. A significantly worse prognosis was noted in the case of radiation alone compared to radiochemotherapy.

A significantly worse prognosis was noted in the case of radiation alone compared to radiochemotherapy. Factors which decreased OS were: the type of therapy and performance status. A significantly worse prognosis was noted in the case of radiation alone compared to radiochemotherapy.

References
1. Krajowy Rejestr Nowotworów - Nowotwory złośliwe oplucnej i płuc (C33–34). http://onkologia.org.pl/nowotwory-zlosliwe-oplucnej-i-pluc-c33-34/. 2. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(Suppl): e1–e295, doi: 10.1378/chest.12-2345, indexed in PubMed: 23649439. 3. Moura MA, Bergmann A, Aguia SS, et al. The magnitude of the association between smoking and the risk of developing cancer in Brazil: a multicenter study. BMJ Open. 2014; 4(2): e003736, doi: 10.1136/bmjopen-2013-003736, indexed in PubMed: 24519874. 4. Ginsberg JR. Thoracic surgery. Churchill-Livingstone, Philadelphia 2002. 5. EUROCAR - Survival of cancer patients in Europe. https://ve3.jsi.svs/EURSResults/forms/S40007.aspx. 6. Krzakowski M, Jassem J, Dzidziuszko R, et al. Nowotwory płucy i oplucnej oraz śródpierśc. 2003: 71. 7. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128(1): 452–462, doi: 10.1378/chest.128.1.452, indexed in PubMed: 16002972. 8. Gray JE, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24): 2342–2350, doi: 10.1056/NEJMoa1809697, indexed in PubMed: 30280658. 9. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985; 312(25): 1604–1608, doi: 10.1056/NEJM198506203122504, indexed in PubMed: 4000199. 10. Eberhardt WEE, De Ruyscher D, Weder W, et al. Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: advanced-stage III non-small-cell lung cancer. Ann Oncol. 2015; 26(8): 1573–1588, doi: 10.1093/annonc/mdv187, indexed in PubMed: 25897013. 11. Blanke CD, Johnson DH. Combined modality therapy in non–small cell lung cancer. Curr Opin Oncol. 1995; 7(2): 144–149, doi: 10.1097/00001849-199503000-00009, indexed in PubMed: 7756379. 12. Cakir S, Egehan I. A randomized clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer. 2004; 43(3): 309–316, doi: 10.1016/j.jungcan.2003.09.009, indexed in PubMed: 15165089. 13. Groen HJM, van der Leest AHW, Fokkema E, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small–cell lung cancer: a multicenter phase III study. Ann Oncol. 2004; 15(3): 427–432, doi: 10.1093/annonc/mdh100, indexed in PubMed: 14998844. 14. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990; 323(14): 940–945, doi: 10.1056/NEJM199010043231403, indexed in PubMed: 2169587. 15. O’Rourke N, Roque I Figuls M, Farré Bernadó N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010(6): CD002140, doi: 10.1002/14651858.CD002140.pub3, indexed in PubMed: 20556756. 16. Huber RM, Flintje M, Schmidt M, et al. Bronchial Carcinoma Therapy Group. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non–small-cell lung cancer: study CTR99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol. 2006; 24(27): 4397–4404, doi: 10.1200/JCO.2005.05.4163, indexed in PubMed: 16983107. 17. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19): 1452–1460, doi: 10.1093/jnci/dj1325, indexed in PubMed: 21903745. 18. Auperin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small–cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190, doi: 10.1200/JCO.2009.26.2543, indexed in PubMed: 20351327. 19. Belani CP, Wang W, Johnson DH, et al. Eastern Cooperative Oncology Group. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.

Conflict of interest: none declared

Marcin Kurowicki
Nu-Med Radiotherapy Center
ul Królewiecka 146
82-300 Elblag, Poland
E-mail: marcin.kurowicki@nu-med.pl

Accepted: 24 May 2020

Received: 6 Feb 2020
20. Provencio M, Isla D, Sánchez A, et al. Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. J Thorac Dis. 2011; 3(3): 197–204, doi:10.3978/j.issn.2072-1439.2011.01.02, indexed in Pubmed: 22263088.

21. Gouda YS, Kohail HM, Eldeeb NA, et al. Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with or without prior induction chemotherapy in patients with locally advanced non-small cell lung cancer. J Egypt Natl Canc Inst. 2006; 18(1): 73–81, indexed in Pubmed: 17237853.

22. Jalal SI, Riggis HD, Melnyk A, et al. Hoosier Oncology Group, US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008; 26(35): 5755–5760, doi: 10.1200/JCO.2008.17.7840, indexed in Pubmed: 19001323.

23. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16(2): 187–199, doi: 10.1016/S1470-2045(14)71207-0, indexed in Pubmed: 25601342.

24. Walraven I, Damhuis RA, Ten Berge MG, et al. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium. Clin Oncol (R Coll Radiol). 2017; 29(11): e177–e185, doi: 10.1016/j.clon.2017.07.012, indexed in Pubmed: 28780009.

25. Osowiecka K, Rucińska M, Kazarnowicz A, et al. Przeżycia chorych na niedrobnokomórkowego raka płucu leczonych napromienianiem w latach 2003–2006 w Samodzielnym Publicznym Zakładzie Opediki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie. NOWOTWORY J Oncol. 2015; 65(1): 14–22, doi: 10.5603/njo.2015.0003.